Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

02 January 2022: Clinical Research

Retrospective Study of 573 Patients with Heart Failure Evaluated for Coronary Artery Disease at Toulouse University Center, France

Antoine Deney 1ABCDEF* , Vanessa Nader 12ABCDEF* , Anthony Matta 13ABCDE , Romain Itier 1CDE , Pauline Fournier 1ABCD , Olivier Lairez 1ADF , Nathalie Pizzinat 4ACD , Didier Carrié 1ACD , Frédéric Boal 4ACD , Michel Galinier 1ACD , Oksana Kunduzova 4ACD , Rania Azar 2ACD , Jerome Roncalli 14ABCDEFG*

DOI: 10.12659/MSM.934804

Med Sci Monit 2022; 28:e934804

Table 1 Characteristics of the studied population stratified by type of heart failure.

Studied populationN=573HFpEFN=89HFrEFN=484P-value
Age68.28±12.2572.53±9.7267.50±12.51
Male sex438 (76.44%)63 (70.78%)375 (77.48%)0.171
BMI27.89±18.10427.65±6.56527.93±19.5010.893
Coronary artery disease320 (55.84%)50 (56.18%)270 (55.78%)0.945
Atrial fibrillation174 (30.37%)25 (28.09%)149 (30.78%)0.611
Chronic kidney disease266 (46.42%)45 (50.56%)221 (45.66%)0.500
Dyslipidemia164 (28.62%)39 (43.82%)125 (25.83%)0.001
Diabetes mellitus171 (29.84%)29 (32.58%)142 (29.34%)0.711
Hypertension309 (53.93%)61 (68.54%)248 (51.24%)0.006
Smoking144 (25.13%)11 (12.36%)133 (27.48%)0.001
Family history89 (15.53%)11 (12.36%)78 (16.12%)0.289
Valvulopathy224 (39.09%)29 (32.58%)195 (40.29%)0.181
Right ventricular dysfunction110 (19.20%)6 (6.74%)104 (21.49%)0.535
TAPSE16.77±4.4516.45±3.48816.78±4.500.811
PAPSE41.38±13.3040.62±10.2641.46±3.630.829
Pacemaker41 (7.16%)6 (6.74%)35 (7.23%)0.858
Defibrillator38 (6.63%)1 (1.12%)37 (7.64%)0.023
NYHA class
 123 (4.01%)04 (0.82%)0.433
 2143 (24.96%)17 (19.10%)126 (26.03%)
 3149 (26.00%)20 (22.47%)129 (26.65%)
 447 (8.20%)4 (4.49%)43 (8.88%)
Systolic blood pressure128.86±22.80137.72±22.43127.37±22.550.001
Diastolic blood pressure75.27±15.8472.92±20.5675.67±14.900.197
Heart rate82.07±20.7977.91±17.9582.76±21.160.081
Troponin143.87±543.08112.13±212.21149.21±580.790.726
NT-ProBNP5535.15±8523.844073.81±7245.545770.14±8697.020.140
β-blockers324 (56.54%)41 (46.06%)283 (58.47%)0.030
Diuretics328 (57.24%)50 (56.18%)278 (57.44%)0.809
Mineralocorticoids95 (16.58%)11 (12.36%)84 (17.35%)0.277
ACE/ARA289 (50.44%)51 (57.30%)238 (49.17%)0.164
ARNI45 (7.85%)3 (3.37%)42 (8.68%)0.087
Ivabradine7 (1.22%)07 (1.45%)0.603
SAPT172 (30.02%)36 (40.45%)136 (28.10%)0.041
DAPT47 (8.20%)8 (9.00%)39 (8.05%)0.893
DOAC+AVK165 (28.79%)27 (30.33%)138 (28.51%)0.799
AAP+OAC35 (6.11%)6 (6.74%)29 (6.00%)0.893
β-blockers480 (83.77%)58 (65.17%)422 (87.19%)
Diuretics439 (76.61%)62 (69.66%)377 (77.89%)0.067
Mineralocorticoids231 (40.31%)19 (21.35%)212 (43.80%)
ACE/ARA332 (57.94%)65 (73.03%)267 (55.16%)0.002
ARNI137 (23.90%)4 (4.49%)133 (27.48%)
Ivabradine19 (3.32%)2 (2.25%)17 (3.51%)0.752
SAPT120 (20.94%)33 (37.08%)87 (17.97%)
DAPT215 (37.52%)29 (32.58%)186 (38.43%)0.256
DOAC+AVK217 (37.87%)31 (34.83%)186 (38.43%)0.480
AP+OAC82 (14.31%)11 (12.36%)71 (14.67%)0.569
BMI – body mass index; APT – single anti-platelet therapy; DAPT – dual anti-platelet therapy; DOAC – direct oral anti-coagulant; AP+OAC – anti-platelet +oral anti-coagulant.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750